Barrett’s esophagus is a major risk factor for esophageal adenocarcinoma.
Photodynamic therapy (PDT) is a treatment where tissue damage is caused by the action of light on a previously administered photosensitizing agent.
In this study, researchers evaluated the long-term efficacy of this treatment in patients with dysplastic Barrett’s esophagus. The team's results are published in the June issue of Endoscopy.
The researchers included a total of 40 patients with low-grade dysplasia in Barrett’s esophagus.
| Macroscopic reduction in the area of the columnar epithelium occurred in 88 % of patients.|
Patients were treated with oral 5-aminolaevulinic acid (ALA) at a dose of 30 mg/kg. This was followed by laser endoscopy 4 hours later. The team treated the patients between 1995 and 1998, and followed them with regular endoscopy and biopsies.
The researchers observed a macroscopic reduction in the area of the columnar epithelium in 88 % of patients. In addition, dysplasia eradicated at 1 month in all patients.
The team has found that this effect was maintained for a median follow-up of 53 months.
However, 1 patient developed a late carcinoma in an untreated area of Barrett’s esophagus 3 years after the intervention.
Dr Ackroyd's team concluded, "Safe and effective ablation of low-grade dysplastic Barrett’s esophagus can be achieved with the use of ALA-induced PDT, and the effects are maintained in the long term".